Type of diabetes-Type 2 Page 2 Posts on Medivizor
Navigation Menu

Type of diabetes-Type 2 Posts on Medivizor

Does empagliflozin help lower blood pressure in patients with diabetes and high night time blood pressure?

Posted by on Mar 17, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to monitor blood pressure changes with empagliflozin (Jardiance) treatment and normal blood pressure treatment in patients with type 2 diabetes (T2D) and uncontrolled night time high blood pressure. The main finding of the study was that these patients had reductions in their blood pressure when empagliflozin was...

Read More

Does canagliflozin increase the risk of bone fractures in patients with type 2 diabetes?

Posted by on Mar 7, 2019 in Diabetes mellitus | 0 comments

In a nutshell This study aimed to investigate the effect of canagliflozin (Invokana) use on bone fracture risk in patients with type 2 diabetes (T2D). The main finding of the study was that there was no increased risk of bone fractures with canagliflozin use. Some background Canagliflozin is an SGLT-2 inhibitor, used to treat T2D. It works by...

Read More

Looking for patients with type 2 diabetes to test new treatment BTI320

Posted by on Feb 17, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study is the test the effectiveness of new drug BTI320 on blood glucose control in type 2 diabetes (T2D). The main outcome to be measured will be a change in blood glucose 2 hours after meals. This study is being carried out in the United States. The details The number of patients with T2D is constantly on the rise....

Read More

Diacerein reduces liver scarring in diabetic patients with non-alcoholic fatty liver disease

Posted by on Feb 15, 2019 in Diabetes mellitus | 0 comments

In a nutshell This study aimed to investigate how effective diacerein is in reducing fat deposits and scarring on the liver in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). The main finding of the study was that diacerein reduced liver scarring in these patients. Some background T2D is commonly associated with...

Read More

The effect of switching from pioglitazone to dapagliflozin on weight and blood glucose control in type 2 diabetes

Posted by on Jan 17, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to compare the effects of switching from pioglitazone to dapagliflozin on body weight and blood glucose control in the treatment of type 2 diabetes (T2D). The main finding was that there was greater weight loss seen with dapagliflozin, with similar blood glucose control. Some background In T2D,...

Read More

Searching for patients with painful diabetic nerve disease to test if spinal cord stimulation can reduce pain

Posted by on Dec 28, 2018 in Diabetes mellitus | 0 comments

In a nutshell This trial is examining the effectiveness of spinal cord stimulation (SCS) on improving nerve function and pain in patients with diabetic nerve disease. The main outcome to be measured will be a change in pain levels, symptoms, and functions. This study is being conducted at the Mayo Clinic in Rochester, Minnesota, United...

Read More

The effect of drugs that protect nerves in the early stage of diabetic eye disease

Posted by on Dec 11, 2018 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to assess whether giving drugs that protect nerves (brimonidine and somatostatin) into the eye can prevent or stop nerve damage in the eye of patients with type 2 diabetes (T2D). The main finding of this study was these drugs protected patients with nerve damage in the eye from the disease worsening. Some...

Read More

How effective is self-management with empagliflozin in the treatment of type 2 diabetes?

Posted by on Dec 8, 2018 in Diabetes mellitus | 0 comments

In a nutshell This study aimed to see how effective intermittent use of empagliflozin (Jardiance) controlled by the patients is in the treatment of poorly controlled type 2 diabetes (T2D). The main finding of the study was that intermittent use of empagliflozin controlled blood sugars as effectively as those who take it every day. Some background...

Read More

Insulin or enhanced oral anti-diabetic tablet therapy in uncontrolled type 2 diabetes?

Posted by on Dec 5, 2018 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to investigate the effects of starting insulin therapy versus enhancing oral tablet therapy after failure with three oral anti-diabetic (OAD) tablets in patients with type 2 diabetes (T2D). The main finding of the study was that adding insulin after failure with three OADs was effective, however, it increased...

Read More

Is long-acting and fast-acting insulin combination injection as safe and effective as taking each separately?

Posted by on Dec 1, 2018 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to compare the effectiveness and safety of insulin degludec/insulin aspart (IDegAsp) combination once daily (OD) versus insulin glargine (IGlar) U100 OD+insulin aspart (IAsp) OD in patients with type 2 diabetes (T2D). The main finding of this study was that IDegAsp achieved similar blood sugar control and...

Read More

Evaluating the safety and effectiveness of a new drug for type 2 diabetes: LY3298176

Posted by on Oct 26, 2018 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the effectiveness and safety of a new drug, LY3298176 for patients with Type 2 diabetes (T2D). The main finding of the study is that LY3298176 improved blood sugar control and was safe to use in these patients. Some background Insulin is a hormone that controls blood sugar. Patients with type 2 diabetes...

Read More

Evaluating the effects of dapagliflozin on fatty liver and liver scarring in Type 2 diabetes

Posted by on Sep 16, 2018 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effects of dapagliflozin (Farxiga) on the build-up of fat and scar tissue in the liver of patients with Type 2 diabetes (T2D) and fatty liver disease. This study concluded that dapagliflozin may reduce fat buildup and scarring in the liver in these patients. Some background About 40 – 50% of patients with...

Read More